Search research articles
Contact Us
Filters
Showing results (51-60 of 64) with videos related to
Page
of 7
Sort By:
International Journal of Cancer
|
January 27, 1997
A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer
H Veelken, A Mackensen, M Lahn, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals
|
April 25, 2007
Development and validation of a phosphorylated SMAD ex vivo stimulation assay
D L Farrington, J M Yingling, J A Fill, et al.
Cardiovascular Toxicology
|
December 10, 2014
Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study
Richard J Kovacs, Giuliana Maldonado, Analia Azaro, et al.
European Surgical Research. Europaische Chirurgische Forschung. Recherches Chirurgicales Europeennes
|
January 1, 1997
Processing of tumor tissues for vaccination with autologous tumor cells
M Lahn, G Köhler, C Schmoor, et al.
Immuno-Oncology Technology
|
May 26, 2023
Characterization and translational development of IOA-289, a novel autotaxin inhibitor for the treatment of solid tumors
M A Deken, K Niewola-Staszkowska, O Peyruchaud, et al.
Investigational New Drugs
|
December 23, 2014
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer
Jordi Rodón, Michael Carducci, Juan M Sepulveda-Sánchez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 27, 2014
First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma
Jordi Rodon, Michael A Carducci, Juan M Sepulveda-Sánchez, et al.
Neuro-Oncology
|
February 24, 2016
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma
Alba A Brandes, Antoine F Carpentier, Santosh Kesari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 5, 2019
Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes
Valeria Santini, David Valcárcel, Uwe Platzbecker, et al.
International Journal of Molecular Sciences
|
May 9, 2017
Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine
David Capper, Andreas von Deimling, Alba A Brandes, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 64) with videos related to
Sort By:
Page
of 7
International Journal of Cancer
|
January 27, 1997
A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer
H Veelken, A Mackensen, M Lahn, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals
|
April 25, 2007
Development and validation of a phosphorylated SMAD ex vivo stimulation assay
D L Farrington, J M Yingling, J A Fill, et al.
Cardiovascular Toxicology
|
December 10, 2014
Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study
Richard J Kovacs, Giuliana Maldonado, Analia Azaro, et al.
European Surgical Research. Europaische Chirurgische Forschung. Recherches Chirurgicales Europeennes
|
January 1, 1997
Processing of tumor tissues for vaccination with autologous tumor cells
M Lahn, G Köhler, C Schmoor, et al.
Immuno-Oncology Technology
|
May 26, 2023
Characterization and translational development of IOA-289, a novel autotaxin inhibitor for the treatment of solid tumors
M A Deken, K Niewola-Staszkowska, O Peyruchaud, et al.
Investigational New Drugs
|
December 23, 2014
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer
Jordi Rodón, Michael Carducci, Juan M Sepulveda-Sánchez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 27, 2014
First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma
Jordi Rodon, Michael A Carducci, Juan M Sepulveda-Sánchez, et al.
Neuro-Oncology
|
February 24, 2016
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma
Alba A Brandes, Antoine F Carpentier, Santosh Kesari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 5, 2019
Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes
Valeria Santini, David Valcárcel, Uwe Platzbecker, et al.
International Journal of Molecular Sciences
|
May 9, 2017
Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine
David Capper, Andreas von Deimling, Alba A Brandes, et al.
Page
of 7